Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?
Jiun-Ruey Hu1, Alexandra N Schwann2, Jia Wei Tan3
1Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address: https://twitter.com/ruey_hu.
Abstract:
The conventional sequence of guideline-directed medical therapy (GDMT) initiation in heart failure with reduced ejection fraction (HFrEF) assumes that the effectiveness and tolerability of GDMT agents mirror their order of discovery, which is not true. In this review, the authors discuss flexible GDMT sequencing that should be permitted in special populations, such as patients with bradycardia, chronic kidney disease, or atrial fibrillation. Moreover, the initiation of certain GDMT medications may enable tolerance of other GDMT medications. Most importantly, the achievement of partial doses of all four pillars of GDMT is better than achievement of target dosing of only a couple.
More Related Videos
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Cardiomyopathy V: Interprofessional Care
